Tessa + Ipamorelin 18mg

FDA-approved GHRH analog (Tessa / Tessa) paired with selective GHRP (Ipamorelin). The strongest evidence-base GH secretagogue stack — Tessa’s FDA approval provides the most robust GHRH human data of any analog.

GH / PerformanceTessa FDAGHRH AnalogIpamorelin GHRP18mg CombinationInjectable

QUICK FACTS

TESSAFDA-approved GHRH analog — Tessa for HIV lipodystrophy

IPAMORELINSelective GHRP — no cortisol elevation

STACK LOGICFDA-grade GHRH + cleanest GHRP = optimal GH research stack

VS CJC STACKTessa has stronger FDA clinical evidence than CJC-1295

DOSINGCombined 18mg vial configuration

Overview

The Tessa + Ipamorelin combination is the strongest evidence-base GH secretagogue stack available. Tessa is the only FDA-approved GHRH analog (Tessa — approved 2010 for HIV-associated lipodystrophy), giving it a human clinical evidence foundation that no other GHRH analog possesses. Phase III data demonstrates GH stimulation, IGF-1 elevation, and trunk fat reduction. Paired with Ipamorelin (selective GHRP with no cortisol elevation), the combination delivers GHRH amplitude enhancement plus GHRP frequency enhancement with the benefit of Tessa’s FDA-track record. The key differentiator from CJC-1295 + Ipamorelin: Tessa has Phase III FDA-level clinical data while CJC-1295 has Phase I/II data only. Available as a combined 18mg vial.

Research Areas

GHRH receptor pharmacologyFDA-approved GHRH analog researchGH axis dual-activation researchLipodystrophy researchBody composition researchSelective GHRP combination research

Available Evidence

FDA-Approved (Tessa)Phase III data: GH stimulation, IGF-1 elevation, trunk fat reduction in HIV lipodystrophy. FDA-approved 2010. Strongest GHRH evidence base of any analog.

Clinical (Ipamorelin)Phase I/II human data — selective GH stimulation without cortisol or prolactin elevation.

MechanisticGHRH amplitude (Tessa) x GHRP frequency (Ipamorelin) for maximal GH pulse output.

Documented Research Benefits

FDA GHRH evidence

Tessa Phase III

GH pulse amplitude

GHRH agonism

GH pulse frequency

Ipamorelin GHRP

No cortisol elevation

Ipamorelin selectivity

IGF-1 elevation

combined

Lipodystrophy research

Tessa FDA

What are you researching?

Tell us your focus area and we’ll send a personalized research guide.

Safety & Regulatory Status

Tessa has Phase III safety data. Ipamorelin physician practice data. Off-label beyond FDA-approved indication. Not for use as weight loss treatment. All information educational reference only.